We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intelligent Ultrasound Group Plc | LSE:IUG | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.50 | 15,048 | 08:00:09 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.00 | 11.00 | 10.75 | 10.50 | 10.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electromedical Apparatus | 11.17M | -2.58M | -0.0079 | -13.29 | 34.32M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:15:51 | O | 4,172 | 10.315 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/7/2024 | 08:19 | UK RNS | Intelligent Ultrasound Group PLC Proposed sale of Clinical AI Business for.. |
| 18/6/2024 | 16:54 | UK RNS | Intelligent Ultrasound Group PLC Result of AGM |
| 23/5/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC Notice of AGM and 2023 Report and Accounts |
| 07/5/2024 | 16:20 | UK RNS | Intelligent Ultrasound Group PLC Holding(s) in Company |
| 01/5/2024 | 13:14 | ALNC |  EARNINGS: Anexo revenue up; Maintel hails "confident start" to 2024 |
| 01/5/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC Final Results |
| 19/4/2024 | 11:41 | ALNC | Intelligent Ultrasound launches GE AI software on ultrasound machines |
| 19/4/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC Notice of Results |
| 19/4/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC Sonolyst launched on Voluson Signature.. |
| 29/2/2024 | 14:24 | ALNC | TRADING UPDATES: Itim revenue up 15%; Aminex completes seismic dataset |
Intelligent Ultrasound (IUG) Share Charts1 Year Intelligent Ultrasound Chart |
|
1 Month Intelligent Ultrasound Chart |
Intraday Intelligent Ultrasound Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/7/2024 | 10:39 | Intelligent Ultrasound. Clinical AI software | 523 |
| 26/4/2023 | 09:27 | Intelligent Ultrasound Group | 113 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 12:15:52 | 10.32 | 4,172 | 430.34 | O |
| 2024-07-26 11:52:04 | 10.32 | 500 | 51.58 | O |
| 2024-07-26 10:45:39 | 10.77 | 10,000 | 1,076.90 | O |
| 2024-07-26 09:26:36 | 11.00 | 77 | 8.47 | O |
| 2024-07-26 09:26:36 | 11.00 | 150 | 16.50 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Intelligent Ultrasound Daily Update Intelligent Ultrasound Group Plc is listed in the Electromedical Apparatus sector of the London Stock Exchange with ticker IUG. The last closing price for Intelligent Ultrasound was 10.50p.Intelligent Ultrasound currently has 326,869,921 shares in issue. The market capitalisation of Intelligent Ultrasound is £34,321,342. Intelligent Ultrasound has a price to earnings ratio (PE ratio) of -13.29. This morning IUG shares opened at 10.50p |
Posted at 23/7/2024 07:31 by oliversydney The current valuation is now 34 million but considering there is a cash offer of 40 million and a retained business with a 10 million turnover and good prospects the share price does look too low |
Posted at 22/7/2024 13:44 by bamboo2 Hi 40F and bmc, thank you for your thoughts.GEHC had flagged up a supply backlog, which led to reduction in Ultrasound deliveries on their Q1 update. They have some very long lead times for certain machines, and this won't have helped our sales. It's a shame that the two co's could not find a way to agree on new terms, however this sale does remove much of the reliance and focus on a single customer. I would have preferred GEHC to take the whole co really, and this was my hope when first getting involved back in late 2022 and early 2023. With regard to other possibilities, TRX is at a similar point in maturity to IUG as they move into profit. I also like FNX. Parent and co-owner of IUG, IPGroup [IPO] is at all time lows, and may be worth a look, although management come across as weak. |
Posted at 22/7/2024 11:24 by bmcollins @40 FathomsI take my hat off to you for sharing your thoughts on our "rump business"now that GEHC have got their hands on the one I'd have preferred we kept. Certainly your input on this co has been very much on the money, GEHC deal being the proof there. I guess if we do get out of the rump for circa £30m that won't be such a bad result, all things considered, though I suspect most shareholders would have preferred to see IUG develop organically, but it is what it is... Thanks again for sharing your knowledge with us. |
Posted at 21/7/2024 18:09 by bamboo2 UK InvestorIntelligent Ultrasound (LON: IUG) is selling its Clinical AI operations to GE. The payment will be £40.5m. So far, £12.2m has been invested in the development of AI. The consideration is equivalent to 12.4p/share. This deal does not include the NeedleTrainer and NeedleTrainer Plus products or the simulation business. The remaining business had annual revenues of £10m last year. Lower simulation sales meant that the latest interim revenues fell from £6.1m to £5.3m. That includes £1.5m from Clinical AI, compared with £2m for the whole of the previous year. There are plans to return a substantial amount of this cash to investors. The share price jumped 44.8% to 10.5p. |
Posted at 18/7/2024 09:13 by bamboo2 Intelligent Ultrasound Group PLC Proposed sale of Clinical AI Business for £40.5m 18/07/2024 8:19amProposed sale of the Clinical AI Business to GE HealthCare for £40.5 million Notice of General Meeting Trading update Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound AI software and simulation company, is pleased to announce it has entered into a conditional sale and purchase agreement for the sale of its Clinical AI business (Intelligent Ultrasound Limited and certain other clinical AI related assets) to GE HealthCare for an enterprise value of £40.5 million on a cash free/debt free basis (the "Proposed Transaction"). The Proposed Transaction excludes the NeedleTrainer and NeedleTrainer Plus products which will remain within the Company along with the Simulation Business. Transaction highlights: · Sale of the Clinical AI Business to GE HealthCare agreed for an enterprise value of £40.5 million. · Disposal excludes the NeedleTrainer/Traine · The consideration represents a implied value of 12.4p per Ordinary Share on current issued share capital and a premium of 70.9 per cent to the Ordinary Share price on 17 July 2024 and a premium of 30.9 per cent to the volume weighted share price for the last 12 months. The Proposed Transaction also values the Clinical AI Business at 33.8 times full year 2023 revenues of that business. · The transaction is subject to shareholder approval under AIM Rule 15, as well as confirmations from the Competition and Markets Authority under the Enterprise Act, and the Investment Security Unit under the National Security and Investment Act, that they do not oppose the transaction (the "Regulatory Consents") · It is the Board's intention to make a material return of capital following a review of the growth potential and capital requirements of the post-transaction business and taking legal and tax advice on structure of a return. An announcement detailing the proposed use of funds and future strategic direction for the post-transaction business is expected to be made by the time of completion of the Proposed Transaction, which, dependent on the timing of the Regulatory Consents, is expected to be in September/October this year. · The Company has received irrevocable undertakings and letters of intent from certain Shareholders (including the Directors) representing approximately 54.6 per cent of the Ordinary Share capital to vote in favour of the Resolution. Further details of the Proposed Transaction are set out below. The Board of Intelligent Ultrasound is committed in its duty to provide value to shareholders and therefore has continually sought to evaluate strategic options available to the Company to do so. For some time the Board has been considering how best to optimise and accelerate the growth of the Clinical AI Business. The Company acquired its Clinical AI Business in October 2017 through its purchase of Intelligent Ultrasound Limited, a University of Oxford spin-out company, for £3.6 million and has committed capital to it to date of approximately £12.2 million (as adjusted to remove NeedleTrainer development costs but including the £3.6 million initial purchase price). Whilst the Board takes great pride in the development capability that has been created in the Clinical AI Business, to date, the growth of the ScanNav related AI revenue streams has been slower than was originally forecast. Furthermore, the Company has not yet reached commercial terms with GE HealthCare for all the future products on its women's health roadmap. Materially growing the value of the Clinical AI Business therefore relies on also developing products outside the existing relationship with GE HealthCare, including ScanNav FetalCheck (for gestational age estimation) and ScanNav Liver (to support hepatologists diagnose and monitor MASH and MAFLD). Although the Company has supportive Shareholders, it has never been able to achieve the up-front funding levels of its competitors and, with financing conditions for small growth companies uncertain, the probable additional investment required must be balanced against ongoing execution risk and the Company's goal of reaching profitability on current cash resources. When assessing the value of the Clinical AI Business, the Board has taken into account the following elements: · the current and expected revenues from royalties paid by GE HealthCare for the use of the ScanNav Assist ultrasound AI software under the Women's Healthcare Licence; · the current and potential value of the ScanNav Anatomy PNB product; · the potential value of the ScanNav FetalCheck gestational age product; and · the value of the Group's future products such as ScanNav Liver, as well as the value of the broader technology and capabilities of the business and its team. The Board considers that GE HealthCare's offer represents a fair net present value for these revenue streams, taking into account the current value accorded to the Company by the capital markets, the expected execution risk and potential dilution required to make the requisite investment in the Clinical AI Business. Notice of General Meeting The Company will shortly post a Circular to Shareholders regarding the Proposed Transaction, which sets out a Notice of General Meeting, and a Form of Proxy for the proposed resolutions. These documents will also be available on the Company's website. Current Trading and Outlook: The Company today also issues a trading update for the period ended 30 June 2024. Unaudited revenue in the first half of the year declined by 18% to £5.1 million (H1 2023: £6.1 million), with simulation sales (excluding NeedleTrainer) down 34% to £3.5 million (H1 2023: £5.3 million). This results from a decline in the UK and North American markets · The decline in UK sales was expected, due to previously flagged NHS budget pressure, reducing sales almost 60% to £0.8 million (H1 2023: £1.9 million) · However, the 23% decline in North America sales to £2.2 million (H1 2023: £2.8 million) was not anticipated, with nearly £0.8 million of expected sales held in delivery backlog or last-minute purchase order delays. Positives in the first half were: · ROW reseller sales growing over 30% to £1.6 million (H1 2023: £1.1 million); and · Clinical AI related revenue doubling to £1.5 million (2023: £0.7 million) of which NeedleTrainer increased to £1.0 million (H1 2023: £0.5 million). · Cash overheads in the business were £4.3 million (H1 2023: £4.9 million) and reflect a number of cost saving across the Group. · Cash burn reduced significantly in H1 2024 to £2.0 million (H1 2023: £3.8 million) leaving cash as at 30 June of £1.0 million (31 December 2023: £3.0 million). Irrevocable undertakings Completion is conditional upon, inter alia, the passing of the Resolution by Shareholders at the General Meeting. The Company has received irrevocable voting undertakings and letters of intent to vote in favour of the Resolution from certain Shareholders (including the Directors) representing approximately 54.6 per cent of the Ordinary Share capital. Amendment to the M&A Bonus arrangement The Remuneration Committee proposes to make the following changes to the M&A Bonus that it put in place for executives in December 2020 following consultation with its major shareholders: · Thresholds to be adjusted in line with the Company's benchmark index, the FTSE AIM All Share. · The threshold will be determined by gross total shareholder return per share ie including all gross amounts returned to shareholders. o Following Completion, Nick Sleep, the Chief Technology Officer, will transfer with the Clinical AI Business and leave the M&A Bonus. If the minimum threshold is reached the minimum bonus payment will be 50% of annual salary. The participation of the Executive Directors, Stuart Gall and Helen Jones in the M&A Bonus scheme constitutes a 'related party transaction' under the AIM Rules. The independent Directors (being the Directors other than Stuart Gall and Helen Jones) consider (having consulted with the Company's nominated adviser, Cavendish) that the terms of the M&A Bonus and the proposed amendment are fair and reasonable insofar as the Company's Shareholders are concerned. Commenting on the Proposed Transaction, Riccardo Pigliucci, Chairman of Intelligent Ultrasound said: "At Intelligent Ultrasound Plc we have spent the last seven years successfully creating first-to-market AI products and have built a strong capability in real-time automated ultrasound image analysis. When GE HealthCare offered us £40.5 million to acquire our Clinical AI Business, we were pleased that our achievements were recognised but it presented us with the very difficult decision to exit the main market we had chosen for our future growth. To date, the growth of our current ScanNav related clinical AI revenues has been slower than we had originally expected and, most importantly, insufficient to fund the developments needed to materially increase the value of the Clinical AI Business. We have had to recognise that developing products such as ScanNav FetalCheck for gestational age estimation and ScanNav Liver is costly and would require the sort of funding levels that are outside the Group's current cash resources or capital raise capabilities. The Board has therefore concluded that accepting GE HealthCare's offer is in the best interest of the Company's shareholders and represents a fair net present value for these potential future revenue streams and recommends it to shareholders for their approval. The remaining Simulation Business, which will be boosted by the inclusion of the NeedleTrainer range previously reported in our Clinical AI business, is a solid one and the Board will use the time between signing and completion of this Proposed Transaction to conduct a comprehensive review of the business. It is the Board's intention to make a material return of capital following a review of the growth potential and capital requirements of the post-transaction business and taking legal and tax advice on structure of a return. An announcement detailing the proposed use of funds and strategic direction for the Company is expected to be made by the time the Proposed Transaction completes." |
Posted at 14/7/2024 11:34 by bmcollins @40fThanks for this I have just listened to it, very positive. What intrigues me most about our current position is why have healthcare professionals, Dr's etc not been buying IUG stock ? I recall that when Glaxo became a favourite stock on Nasdaq because of the potential of Zantac, the great bulk of the U.S. demand for the stock, in the first instance, came from Dr's & other clinicians who realised how effective it was for stomach ulcers. That was 40 odd years ago & now of course Zantac is a dirty word for GSK. Even a modest number of health professionals buying IUG, given its illiquidity, would have a very positive result on the share price Perhaps this could happen as more people use our facility on their GE machines, I'd like to think so but am not holding my breath ! |
Posted at 08/7/2024 14:00 by bmcollins @40fThanks for this, it is indeed nice to see IUG Cardiff UK in the text In happier times in AIM this would have warranted something of a puff by the company's broker, but these days you rarely see a Nomad / Broker make any comment, even after results are announced. However on the bright side one can argue convincingly that for those with patience this offers an intriguing future and is currently trading at the wrong price. I feel obliged to add some more at these levels, hopefully the share price is at, or very close to, bottom. |
Posted at 08/7/2024 13:24 by 40 fathoms Yes, I am looking forward to it. However, looking at the share price it would suggest many are not !In the meantime a little something for interest more than near term commercial opportunity. It is a paper published by NASA looking at the possible uses of AI for healthcare diagnostics and treatment as they start to explore long duration space flight. Page 11 ScanNav PNB gets a mention. |
Posted at 12/6/2024 09:57 by chester9 AGM on 18th it's in their interests to put out a trading statement given share price If they don't then normally do a TU in late July.Labour will increase spending on NHS they have a strong record on this. That should support companies like IUG. Until news it will drift. |
Posted at 07/9/2023 23:15 by 40 fathoms I think it all depends as we are prisoners to our share price. In the end any offer will be a function of share price at the time and not necessary a reflection of true value.Assuming the companies evolution of revenue and profit comes to pass, I think an offer today would come at about 20p, this would be 30p this time next year. I think in 2025 or 2026 it starts to get interesting as you would then expect the share price to reflect the fact that we would be significantly profitable, with a clear path to GBP 10 million of annual profit and plenty of growth still to come from product development and products under development. I think then an offer would come at well north of 60p. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
